Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

1.

The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man.

Preston GC, Brazell C, Ward C, Broks P, Traub M, Stahl SM.

J Psychopharmacol. 1988 Jan;2(2):67-79. doi: 10.1177/026988118800200202.

PMID:
22155841
[PubMed]
2.

The Revival of Scopolamine Reversal for the Assessment of Cognition-Enhancing Drugs.

Buccafusco JJ.

In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press; 2009. Chapter 17.

3.

Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor.

Snyder PJ, Bednar MM, Cromer JR, Maruff P.

Alzheimers Dement. 2005 Oct;1(2):126-35. doi: 10.1016/j.jalz.2005.09.004.

PMID:
19595845
[PubMed]
4.

Drug discovery in dementia: the role of rodent models.

Van Dam D, De Deyn PP.

Nat Rev Drug Discov. 2006 Nov;5(11):956-70. Review.

PMID:
17080031
[PubMed - indexed for MEDLINE]
5.

Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval.

de Bruin N, Pouzet B.

Pharmacol Biochem Behav. 2006 Sep;85(1):253-60. Epub 2006 Sep 20.

PMID:
16987546
[PubMed - indexed for MEDLINE]
6.

Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women.

Dumas J, Hancur-Bucci C, Naylor M, Sites C, Newhouse P.

Neuropsychopharmacology. 2006 Sep;31(9):2065-78. Epub 2006 Feb 15.

PMID:
16482084
[PubMed - indexed for MEDLINE]
Free Article
7.

Effects of selegiline alone or with donepezil on memory impairment in rats.

Takahata K, Minami A, Kusumoto H, Shimazu S, Yoneda F.

Eur J Pharmacol. 2005 Aug 22;518(2-3):140-4.

PMID:
16061218
[PubMed - indexed for MEDLINE]
8.

The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.

Lieben CK, Blokland A, Sik A, Sung E, van Nieuwenhuizen P, Schreiber R.

Neuropsychopharmacology. 2005 Dec;30(12):2169-79.

PMID:
15957009
[PubMed - indexed for MEDLINE]
Free Article
9.

Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: a randomized, controlled study.

Beglinger LJ, Tangphao-Daniels O, Kareken DA, Zhang L, Mohs R, Siemers ER.

J Clin Psychopharmacol. 2005 Apr;25(2):159-65.

PMID:
15738747
[PubMed - indexed for MEDLINE]
10.

CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases.

Youdim MB, Buccafusco JJ.

J Neural Transm. 2005 Apr;112(4):519-37. Epub 2005 Jan 24. Review.

PMID:
15666041
[PubMed - indexed for MEDLINE]
11.

Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats.

van der Staay FJ, Bouger PC.

Behav Brain Res. 2005 Jan 6;156(1):1-10.

PMID:
15474645
[PubMed - indexed for MEDLINE]
12.

AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors.

Van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, Schreiber R.

Psychopharmacology (Berl). 2004 Apr;172(4):375-83. Epub 2004 Jan 15.

PMID:
14727003
[PubMed - indexed for MEDLINE]
13.

Detecting dementia: novel neuropsychological markers of preclinical Alzheimer's disease.

Blackwell AD, Sahakian BJ, Vesey R, Semple JM, Robbins TW, Hodges JR.

Dement Geriatr Cogn Disord. 2004;17(1-2):42-8. Epub 2003 Oct 13.

PMID:
14560064
[PubMed - indexed for MEDLINE]
14.

The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.

Terry AV Jr, Buccafusco JJ.

J Pharmacol Exp Ther. 2003 Sep;306(3):821-7. Epub 2003 Jun 12. Review.

PMID:
12805474
[PubMed - indexed for MEDLINE]
Free Article
15.

Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat.

Misane I, Ogren SO.

Neuropsychopharmacology. 2003 Feb;28(2):253-64.

PMID:
12589378
[PubMed - indexed for MEDLINE]
Free Article
16.

Behavioral characterization of mild cognitive impairment.

Collie A, Maruff P, Currie J.

J Clin Exp Neuropsychol. 2002 Sep;24(6):720-33.

PMID:
12424647
[PubMed - indexed for MEDLINE]
17.

A computer-assisted cognitive test battery for aged monkeys.

Buccafusco JJ, Terry AV Jr, Murdoch PB.

J Mol Neurosci. 2002 Aug-Oct;19(1-2):179-85.

PMID:
12212778
[PubMed - indexed for MEDLINE]
18.

Multiple central nervous system targets for eliciting beneficial effects on memory and cognition.

Buccafusco JJ, Terry AV Jr.

J Pharmacol Exp Ther. 2000 Nov;295(2):438-46.

PMID:
11046074
[PubMed - indexed for MEDLINE]
Free Article
19.

The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment.

Collie A, Maruff P.

Neurosci Biobehav Rev. 2000 May;24(3):365-74. Review.

PMID:
10781696
[PubMed - indexed for MEDLINE]
20.

Effect of rivastigmine on scopolamine-induced memory impairment in rats.

Bejar C, Wang RH, Weinstock M.

Eur J Pharmacol. 1999 Nov 3;383(3):231-40.

PMID:
10594314
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk